[12] Patent
[11] Patent No.:GC0011337  
[45] Date of Publishing the Grant of the Patent: 1/Jun /2020                63/2020  
Number of the Decision to Grant the Patent:2020/169089
Date of the Decision to Grant the Patent:30/Jun/2020

[21] Application No.:GC 2011-19330

[22] Filing Date:20/9/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
21/9/2010
22/6/2011
5/7/2011
385.058/61
499.994/61
504.616/61

[72] Inventors:1- OR, Yat Sun،2- LONG Jiang ،3- MA, Jun،4- WANG, Bin ،5- WANG, Guoqiang

[73] Owner: Enanta Pharmaceuticals, Inc., 500, Arsenal Street, Watertown, MA 02472, USA

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 38/12, 45/06; C07K 14/81, 5/062, 5/08, 5/083, 5/097, 5/12 (2006.01)

[56] Cited Documents:

-US 2010/0029666 A1 (Harper et al.) 04 February. 2010
-US 2009/0075869 A1 (Holloway et al.) 19 March. 2009
-US 2009/0274657 A1 (Gai et al.) 05 November. 2009
 
Examiner: PH. Nada M. AlBehaiji

[54] MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
[57] Abstract: ABSTRACT The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
No. of claims: 6


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.